Valuation: Mertiva AB

Market Cap 772M 693M 641M 580M 1.08B 73.57B 1.1B 7.66B 3.05B 38.5B 2.9B 2.84B 122B P/E 2018
28.3x
P/E 2019 13.3x
Enterprise Value 689M 619M 572M 518M 968M 65.66B 979M 6.84B 2.72B 34.36B 2.59B 2.53B 109B EV / Sales 2018
-
EV / Sales 2019 -
Free-Float
68.13%
Yield 2018 *
-
Yield 2019 -
28/08/17 Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others. CI
11/08/17 Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd CI
11/07/17 Sanofi Pasteur Inc. agreed to acquire Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others for $750 million CI
29/11/15 Mertiva AB's Equity Buyback announced on December 6, 2012, has expired. CI
18/12/14 Mertiva AB (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million. CI
22/01/14 Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012. CI
11/10/13 Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012. CI
08/10/13 The members of the management of Diamyd, Inc. cancelled the acquisition of 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B). CI
25/09/13 Mertiva AB (OTCPK:DMYD.F) acquired an additional 7.27% stake in Protein Sciences Corporation from Pacific Rim Ventures Co., Ltd. and other shareholders for $8.4 million. CI
27/08/13 Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic All-Share Index CI
30/07/13 Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic Small Cap Index CI
04/07/13 Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012. CI
23/04/13 Diamyd Medical AB Announces Board Appointments CI
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/20 Buy

Chairman

24,314 0.1775%
08/10/20 Buy

Chairman

5,378 0.0393%
08/10/20 Buy

Chairman

821 0.0060%
Change 5-day change 1-year change 3-year change Capi.($)
- 0.00% - - 89.46M
+0.65%-3.36%+36.98%+60.50% 64.14B
+1.76%+1.27%+11.82%+81.21% 55.53B
-0.94%+0.99%+10.45%+100.19% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
+29.06%+47.63%+107.12%+92.73% 34.47B
-2.94%-0.62%+22.96%-10.93% 24.23B
Average +3.82%+4.08%+52.30%+161.94% 39.26B
Weighted average by Cap. +3.33%+3.49%+49.19%+159.64%

Financials

2018 2019
Net sales - -
Net income 25.3M 22.7M 20.99M 19.01M 35.51M 2.41B 35.94M 251M 99.94M 1.26B 94.94M 92.93M 4B 76.99M 69.08M 63.86M 57.84M 108M 7.33B 109M 764M 304M 3.84B 289M 283M 12.18B
Net Debt -253M -227M -210M -190M -355M -24.08B -359M -2.51B -999M -12.6B -949M -929M -40.01B -83.08M -74.54M -68.91M -62.41M -117M -7.91B -118M -824M -328M -4.14B -312M -305M -13.14B
Logo Mertiva AB
Mertiva AB, formerly Diamyd Medical AB, is a Sweden-based company active within the healthcare sector. As of August 31, 2013, the Company owned 8% shares of the United-States based Protein Sciences Corporation, as well as 19% shares of Mercodia AB. The Company changed its name in May 2013. Additionally, its subsidiary, Diamyd Therapeutics, was spun off and changed its name to Diamyd Medical.
Employees
-
  1. Stock Market
  2. Stocks
  3. MERT A Stock